The vasodilatory beta-blockers

Current Hypertension Reports

Volumn 9, Issue 4, 2007, Pages 269-277

  Pedersen, Michala E ^b   Cockcroft, John R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CARTEOLOL; CARVEDILOL; CELIPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; LABETALOL; METOPROLOL; NEBIVOLOL; NIPRADILOL; NITRIC OXIDE; PERINDOPRIL; PINDOLOL; PLACEBO; PRAVASTATIN; PROPRANOLOL; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; AORTA PRESSURE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; HEART STROKE VOLUME; HEMODYNAMICS; HUMAN; HYPERTENSION; MONOTHERAPY; MORTALITY; NONHUMAN; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; STROKE; VASCULAR RESISTANCE; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; ATENOLOL; BENZOPYRANS; BLOOD PRESSURE; CARBAZOLES; CARDIAC OUTPUT; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; HEMODYNAMICS; HUMANS; LABETALOL; PROPANOLAMINES; VASCULAR RESISTANCE; VASODILATION; VENTRICULAR FUNCTION, LEFT;

EID: 34548477190     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0050-2     Document Type: Review

References (69)

1. Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of fite Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
2. Prichard BN, Cruickshank JM, Graham BR: Beta-adrenergic blocking drugs in fite treatment of hypertension. Blood Press 2001, 10:366-386.
3. Lindholm LH, Carlberg B, Samuelsson O: Should β blockers remain first choice in fite treatment of primary hypertension? A meta-analysis. Lancet 2005, 366:1545-1553.
4. Dahlöf B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in fite Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
5. National Institute for Health and Clinical Excellence: Hypertension: management of hypertension in adults in primary care (partial update of NICE clinical guideline 18). NICE clinical guideline 34. Available at: http://www.nice.org.uk/guidance/CG34/niceguidance/pdf/English. Accessed February 21, 2007.
6. Carlberg B, Samuelsson O, Lindholm LH: Atenolol in hypertension: is it a wise choice? Lancet 2004, 364:1684-1689.
7. Khan N, McAlister FA: Re-examining fite eflicacy of β-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006, 174:1737-1742.
8. Khan NA, McAlister FA, Rabkin SW, et al.: The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol 2006, 22:583-593.
9. Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
10. Wilkinson IB, McEniery CM, Cockcroft JR: Atenolol and cardiovascular risk: an issue ciose to fite heart [editorial]. Lancet 2006, 367:627-628.
11. Danchin N, Benetos A, Lopez-Sublet M, et al.: Aortic pulse pressure is related to the presence and extent of coronary artery disease in men undergoing diagnostic coronary angiography: a multicenter study. Am J Hypertens 2004, 17:129-133.
12. Chirinos JA, Zambrano JP, Chakko S, et al.: Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension 2005, 45:980-985.
13. Dhakam Z, McEniery CM, Yasmin, et al.: Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006, 19:214-219.
14. Toda N: Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 2003, 100:215-234.
15. Veverka A, Nuzum DS, Jolly JL: Nebivolol: a third-generation β-adrenergic blocker. Ann Pharmacother 2006, 40:1353-1360.
16. Zanchetti A: Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press 2004, 13(Suppl 1):18-33.
17. Christensen KL, Mulvany MJ: Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey. J Hypertens 2001, 19:1001-1006.
18. Rizzoni D, Porteri E, Boari GE, et al.: Prognostic significance of small-artery structure in hypertension. Circulation 2003, 108:2230-2235.
19. Buus NH, Bøttcher M, Jørgensen CG, et al.: Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or β-blockade in patients with essential hypertension. Hypertension 2004, 44:465-470.
20. Nichols WW: Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005, 18:3S-10S.
21. Dunn CJ, Lea AP, Wagstaff AJ: Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1997, 54:161-185.
22. Afonso RA, Patarrao RS, Macedo MP, Carmo MM: Carvedilol action is dependent on endogenous production of nitric oxide. Am J Hypertens 2006, 19:419-425.
23. Yoshioka T, Iwamoto N, Tsukahara F, et al.: Anti-NO action of carvedilol in cell-free system and in vascular endothelial cells. Br J Pharmacol 2000, 129:1530-1535.
24. Wendt T, van der Does R, Schrader R, et al.: Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol. J Cardiovasc Pharmacol 1987, 10(Suppl 11):S147-S150.
25. Morgan T, Snowden R, Butcher L: Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance. J Cardiovasc Pharmacol 1987, 10(Suppl 11): S124-S129.
26. Moser M, Frishman W: Results of therapy with carvedilol, a β-blocker vasoditator with antioxidant properties, in hypertensive patients. Am J Hypertens 1998, 11:15S-22S.
27. Kanto JH: Current status of labetalol, the first alpha- and beta-blocking agent. Int J Clin Pharmacol Ther Toxicol 1985, 23:617-628.
28. Labetalol Hydrochloride Tablets USP [package insert]. Corona, CA: Watson Laboratories, Inc.; 2000.
29. Opie LH: Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina. Cardiovasc Drugs Ther 1988, 2:369-376.
30. Novo S, Abrignani MG, Sapienza ND, et al.: Partial regression of vascular structural alterations in hypertensive patients treated with alpha-beta-blocker, labetalol. Int Angiol 1992, 11:137-141.
31. Bristow MR, Nelson P, Minobe W, Johnson C: Characterization of β1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium [Abstract P-121]. Am J Hypertens 2005, 18(Pt 2):51A-52A.
32. Pedersen ME, Cockcroft JR: The latest generation of beta-blockers: new pharmacologic properties. Curr Hypertens Rep 2006, 8:279-286.
33. Cockcroft JR, Chowienczyk PJ, Brett SE, et al.: Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995, 274:1067-1071.
34. Dawes M, Brett SE, Chowienczyk PJ, et al.: The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999, 48:460-463.
35. Tzemos N, Lim PO, MacDonald TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001, 104:511-514.
36. Schmitt M, Avolio A, Qasem A, et al.: Basal NO locally modulates human iliac artery function in vivo. Hypertension 2005, 46: 227-231.
37. Mason RP, Kubant R, Jacob RF, et al.: Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol 2006, 48:862-869.
38. McEniery CM, Schmitt M, Qasem A, et al.: Nebivolol increases arterial distensibility in vivo. Hypertension 2004, 44:305-310.
39. Kamp O, Sieswerda GT, Visser CA: Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003, 92:344-348.
40. Galderisi M, Cicala S, D'Errico A, et al.: Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease. J Hypertens 2004, 22:2201-2208.
41. Kouoh F, Gressier B, Dine T, et al.: In vitro and ex vivo antioxidant activities of labetalol on rabbit neutrophil respiratory burst. Adv Ther 2004, 21:178-185.
42. Jaboureck-Bouttier R, Gressier B, Dine T, et al.: Effects of two antihypertensive agents, labetalol and metoprolol, on the production of reactive oxygen species by normal polymorphonuclear leukocytes in vitro. Hypertens Pregnancy 1999, 18:239-247.
43. Saijonmaa O, Metsarinne K, Fyhrquist F: Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture. Blood Press 1997, 6:24-28.
44. Oelze M, Daiber A, Brandes RP, et al.: Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 2006, 48:677-684.
45. Mason RP, Kalinowski L, Jacob RF, et al.: Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of Black Americans. Circulation 2005, 112:3795-3801.
46. Celik T, Iyisoy A, Kursaklioglu H, et al.: Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006, 24:591-596.
47. Fratta-Pasini A, Garbin U, Nava MC, et al.: Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005, 23:589-596.
48. Kuroedov A, Cosentino F, Luscher TF: Pharmacological mechanisms of clinically favorable properties of a selective β1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev 2004, 22:155-168.
49. Sung C-P, Arleth AJ, Ohlstein EH: Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993, 21:221-227.
50. Goa KL, Benfield P, Sorkin EM: Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. Drugs 1989, 37:583-627.
51. Abernethy DR, Bartos P, Plachetka JR: Labetalol in the treatment of hypertension in elderly and younger patients. J Clin Pharmacol 1987, 27:902-906.
52. Flamenbaum W, Weber MA, McMahon FG, et al.: Monotherapy with labetalol compared with propranolol. Differential effects by race. J Clin Hypertens 1985, 1:56-69.
53. von Fallois J, Faulhaber HD: Nebivolol, a beta blocker of the third generation: the current treatment of arterial hypertension: results of a multi-center observational study. Schweiz Rundsch Med Prax 2001, 90:435-441.
54. Van Nueten L, Dupont AG, Vertommen C, et al.: A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997, 11:139-144.
55. Sarafidis PA, Bakris GL: Do the metabolic effects of β-blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens (Greenwich) 2006, 8:351-356.
56. Ambrosioni E, Borghi C: Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective β-blockers in the treatment of hypertension: a meta-analysis. High Blood Press Cardiovasc Prev 2005, 12:27-35.
57. Saunders E, Curry C, Hinds J, et al.: Labetalol compared with propranolol in the treatment of black hypertensive patients. J Clin Hypertens 1987, 3:294-302.
58. Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201-207.
59. Jacob S, Rett K, Wicklmayr M, et al.: Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996, 14:489-494.
60. Giugliano D, Acampora R, Marfella R, et al.: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 1997, 126:955-959.
61. Bakris GL, Fonseca V, Katholi RE, et al.: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. A randomized controlled trial. JAMA 2004, 292:2227-2236.
62. Poirier L, Cléroux J, Nadeau A, Lacourcière Y: Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001, 19:1429-1435.
63. Pesant Y, Marc-Aurèle J, Bielmann P, et al.: Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension. Am J Ther 1999, 6:137-147.
64. Rizos E, Bairaktari E, Kostoula A, et al.: The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003, 8:127-134.
65. Fogari R, Zoppi A, Lazzari P, et al.: Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997, 11:753-757.
66. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385-1390.
67. Otterstad JE, Ford I: The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? Eur J Heart Fail 2002, 4:501-506.
68. Packer M, Coats AJ, Fowler MB, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
69. Flather MD, Shibata MC, Coats AJ, et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26:215-225.